These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32101720)

  • 1. Immune Checkpoint Inhibition in Prostate Cancer.
    Nicholson LT; Fong L
    Trends Cancer; 2020 Mar; 6(3):174-177. PubMed ID: 32101720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the clinical development of immunotherapy in prostate cancer.
    Cordes LM; Gulley JL; Madan RA
    Asian J Androl; 2018; 20(3):253-259. PubMed ID: 29582792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
    Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-targeted therapy in prostate cancer.
    Tagawa ST
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):74-77. PubMed ID: 33596187
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
    Huang L; He J
    Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
    Mans L; Pezzullo M; D'Haene N; Van de Stadt J; Van Laethem JL
    Eur J Cancer; 2020 Aug; 135():75-77. PubMed ID: 32554216
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
    Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
    Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Promising new treatment options for metastatic androgen-independent prostate cancer].
    Tan W
    Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual immunotherapy alternating with anti-PD-1 antibody plus liposomal doxorubicin show good efficacy in prostate epithelioid hemangioendothelioma: a case report.
    Zhang J; Ye Q; Yang X; Li T; Huang S; Zhou P; Feng Y; Liu H; Xie K
    Front Immunol; 2024; 15():1384111. PubMed ID: 38947327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.